Ibrutinib induces rapid down‐regulation of inflammatory markers and altered transcription of chronic lymphocytic leukaemia‐related genes in blood and lymph nodes. (20th August 2018)

• Record Type: Journal Article
• Authors: Palma, Marzia; Krstic, Aleksandra; Peña Perez, Lucia; Berglöf, Anna; Meinke, Stephan; Wang, Qing; Blomberg, K. Emelie M.; Kamali‐Moghaddam, Masood; Shen, Qiujin; Jaremko, Georg; Lundin, Jeanette; De Paepe, Ayla; Höglund, Petter; Kimby, Eva; Österborg, Anders; Månsson, Robert; Smith, C. I. Edvard
• Is Part Of: British journal of haematology. Volume 183:Number 2(2018)
• Page Start: 212
• Page End: 224
• Publication Date: 2018-08-20
• Subjects: chronic lymphocytic leukaemia -- ibrutinib -- chemokines -- RNA sequencing -- flow‐cytometry; Hematology -- Periodicals; Blood -- Diseases -- Periodicals; 616.15
• DOI: 10.1111/bjh.15516
• Languages: English
• ISSNs: 0007-1048

Abstract

Summary: In chronic lymphocytic leukaemia (CLL) patients, treatment with the Bruton tyrosine kinase inhibitor ibrutinib induces a rapid shift of tumour cells from lymph nodes (LN) to peripheral blood (PB). Here, we characterized in depth the dynamics of ibrutinib‐induced inflammatory, transcriptional and cellular changes in different compartments immediately after treatment initiation in seven relapsed/refractory CLL patients. Serial PB and LN samples were taken before start and during the first 29 days of treatment. Changes in plasma inflammation‐related biomarkers, CLL cell RNA expression, B‐cell activation and migration markers expression, and PB mononuclear cell populations were assessed. A significant reduction of 10 plasma inflammation markers, the majority of which were chemokines and not CLL‐derived, was observed within hours, and was paralleled by very early increase of CD19 + circulating cells. At the RNA level, significant and continuous changes in transcription factors and signalling molecules linked to B‐cell receptor signalling and CLL biology was observed in both PB and LN CLL cells already after 2 days of treatment. In conclusion, ibrutinib seems to instantly shut off an ongoing inflammatory response and interfere with diverse sensitive pathways in the LN.